THRIVE-2 met all primary and secondary endpoints at the 15-week primary analysis timepoint after 5 infusions of veligrotug.

Viridian's veligrotug shows promising results in treating TED patients, setting the stage for future growth in the ...

The company’s chronic thyroid eye disease treatment, veligrotug, was able to reduce eye bulge by 56% compared with placebo.

RBC Capital analyst Gregory Renza raised the firm’s price target on Viridian Therapeutics (VRDN) to $47 from $44 and keeps an Outperform rating ...

Viridian Therapeutics (VRDN) announced topline data from the THRIVE-2 phase 3 clinical trial of veligrotug, an intravenously delivered anti-insulin-like growth factor-1 receptor antibody, in patients ...

Viridian Therapeutics stock popped Monday after the company scored a win in thyroid eye disease, a condition that causes the ...

Viridian (VRDN) shares shot up 25% after the company reported positive results from a Phase 3 study of veligrotug in the ...

Experts are issuing a stern warning to drivers: failing to report certain health conditions to the DVLA could lead to hefty ...

According to experts, there are a number of medical conditions that drivers have to tell the DVLA about or risk facing a ...

Recent advice from one of the UK's leading online platforms for selling used cars, BigWantsYourCar.com, stresses the ...

"Drivers who do not report high blood pressure to the DVLA are not just risking a fine—they could also face prosecution if ...